Jim Datin

Jim Datin

Director/Board Member presso ORASURE TECHNOLOGIES, INC.

Patrimonio netto: 538 187 $ in data 31/03/2024

61 anni
Health Technology
Finance
Technology Services

Profilo

Jim A.
Datin
is currently the Chief Executive Officer & Director at BALX Holdings LLC.
He is also an Independent Director at OraSure Technologies, Inc., a Director at Life Sciences Pennsylvania, a Director at Celerant Consulting, Inc., a Director at the Hepatitis B Foundation, a Co-Managing Director at BioAgilytix Europe GmbH, a Director at The North Carolina Biotechnology Center, and an Operating Partner at GHO Capital Partners LLP (starting in 2023).
In his former roles, Mr. Datin served as the Chief Executive Officer of Golden Land Bhd.
He was also the Chief Executive Officer of TouchPoint Solutions from 2004 to 2005.
He held positions as Chairman at Clarient, Inc. and Laureate Biopharmaceutical Services, Inc. Mr. Datin was the EVP & Managing Director-Life Sciences Group at Safeguard Scientifics, Inc. from 2011 to 2013.
He served as the Director of International Business at Merck KGaA and held director positions at Acelerate, Inc., Rubicor Medical, Inc., Sotera Wireless, Inc., Ventaira Pharmaceuticals, Inc., NuPathe, Inc., Putney, Inc., NovaSom, Inc., Intralinks Holdings, Inc., and Smithkline Beckman Corp.
He was the Group Director-Corporate Business Strategy at GlaxoSmithKline, Inc. from 1999 to 2001.
Mr. Datin was also a Director at the University City Science Center and Safeguard International Management LLC.
He served as a Director of International Business at Baxter Corp.
and was an Independent Director at FSD Pharma, Inc. from 2019 to 2021.
He was a Non-Executive Director at BioAgilytix Labs LLC from 2013 to 2022.
Mr. Datin was the Group President at Dendrite International, Inc. in 2004.
He is also a Member of Ben Franklin Technology Partners.
Mr. Datin received his undergraduate degree from Marshall University in 1985.
He earned an MBA from the University of New Haven in 1995.
He also attended The Wharton School of the University of Pennsylvania for his undergraduate studies.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValorizzazioneData di valutazione
26/03/2024 87 510 ( 0.12% ) 538 187 $ 31/03/2024

Posizioni attive di Jim Datin

SocietàPosizioneInizio
ORASURE TECHNOLOGIES, INC. Director/Board Member 11/08/2019
Hepatitis B Foundation Director/Board Member -
Director/Board Member -
Director/Board Member -
Director/Board Member 01/01/2017
Chief Executive Officer -
Chief Executive Officer -
Private Equity Investor 01/03/2023
Tutte le posizioni attive di Jim Datin

Precedenti posizioni note di Jim Datin

SocietàPosizioneFine
Chief Executive Officer 16/06/2022
░░░ ░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░ ░░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
Vedi nel dettaglio l'esperienza di Jim Datin

Formazione di Jim Datin

Marshall University Undergraduate Degree
University of New Haven Masters Business Admin
The Wharton School of the University of Pennsylvania Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Jim Datin

Relazioni

100 +

Relazioni di 1° grado

34

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa5
SAFEGUARD SCIENTIFICS, INC.

Finance

MERCK KGAA

Health Technology

ORASURE TECHNOLOGIES, INC.

Health Technology

GOLDEN LAND

Finance

FSD PHARMA INC.

Health Technology

Aziende private26

Technology Services

Health Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Services

Technology Services

Health Technology

Health Technology

Health Technology

Technology Services

Miscellaneous

Technology Services

Finance

Finance

Commercial Services

Health Technology

Commercial Services

Hepatitis B Foundation

Commercial Services

Health Technology

Commercial Services

Finance

Vedi le connessioni aziendali